FY26 was a strong year for Resonance Health, and we wanted you to hear it directly from us.

Group revenue rose 42% to $15,751,909, and we returned to profit with a net profit after tax of $1,513,109, a turnaround of more than $3.3 million on last year's loss. Normalised EBITDA came in at $2,550,000, ahead of the $2.0 million we originally guided the market to expect, guidance we upgraded during the year and then beat.

Just as important to us is the quality behind those numbers. We collected a record $14,280,910 in cash receipts, generated positive operating cash flow in every quarter, and finished the year with $4,849,447 in the bank against $2,533,334 of bank debt. This growth was funded from our own operations, not from raising capital.

All three parts of our business, our imaging software, our clinical research organisation and our TrialsWest site network, grew and reinforced each other this year. Our major MASH clinical trial finished patient recruitment, which is a real achievement, but it also means replacing that revenue is now our key near-term priority as we head into FY27. Our $2,533,334 NAB facility matures in March 2027, and the Board is actively working on its renewal well ahead of that date. Our liver fibrosis device remains under development, funded from our own cash flow, with no revenue from it assumed in our near-term plans.

We also strengthened the Board this year, appointing Dr David Fuller and Michael Sistenich, whose drug development and healthcare investment experience will support the decisions ahead of us.

The full Annual Report, including the detailed financial statements, sits alongside this summary. If anything here raises a question for you, we'd genuinely like to hear it through the question box on this page.